Abstracts tagged "axial spondyloarthritis and registry"

Abstract Number: 602 • 2019 ACR/ARP Annual Meeting
Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip Mease¹, Mei Liu ², Sabrina Rebello ², Robert McLean ², Blessing Dube ², Meghan Glynn ³, Esther Yi ⁴, Yujin Park ⁵ and Alexis Ogdie ⁶, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, ⁶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that primarily affects the axial skeleton and frequently affects the peripheral joints and entheses. AxSpA…
Abstract Number: 2591 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA). This situation changed when anti-interleukin-17A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].